Increased Serum Levels of the IL-33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis

Scandinavian Journal of Immunology

Volumn 82, Issue 3, 2015, Pages 269-274

  Wagner, A ^a   Kohm M ^a,b   Nordin, A ^c   Svenungsson, E ^c   Pfeilschifter, J M ^a   Radeke, H H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; CYTOKINE RECEPTOR; ILOPROST; INTERLEUKIN 33; PROTEIN SOLUBLE ST2; PROTEIN ST2L; UNCLASSIFIED DRUG; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISEASE DURATION; ENDOTHELIUM CELL; FEMALE; HUMAN; LIMITED CUTANEOUS SYSTEMIC SCLEROSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC SCLEROSIS; VASCULAR FIBROSIS; AUTOIMMUNE DISEASE; BLOOD; DIFFUSE SCLERODERMA; DISEASE COURSE; LIMITED SCLERODERMA; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; HUMANS; ILOPROST; INTERLEUKINS; MALE; MIDDLE AGED; RECEPTORS, SOMATOSTATIN; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; VASODILATOR AGENTS;

EID: 84939218599     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12317     Document Type: Article

References (28)

1. Cayrol C, Girard J. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 2014;31:31-7.
2. Ali S, Mohs A, Thomas M et al. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J. Immunol. 2011;187:1609-16.
3. Mirchandani AS, Salmond RJ, Liew FY. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol 2012;33:389-96.
4. Yang Q, Li G, Zhu Y et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol 2011;41:3351-60.
5. Villarreal DO, Weiner DB. Interleukin 33: a switch-hitting cytokine. Curr Opin Immunol 2014;28:102-6.
6. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 2011;30:825-30.
7. Vettori S, Cuomo G, Iudici M et al. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol 2014;34:663-8.
8. Manetti M, Ibba-Manneschi L, Liakouli V et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 2010;69:598-605.
9. Bergis D, Kassis V, Ranglack A et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol 2013;6:311-8.
10. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.
11. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
12. Camargo C, Sekiyama J, Arismendi M, Kayser C. Microvascular abnormalities in patients with early systemic sclerosis: less severe morphological changes than in patients with definite disease. Scand J Rheumatol 2015;44:48-55.
13. Luzina IG, Kopach P, Lockatell V et al. Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol 2013;49:999-1008.
14. Martínez-Martínez E, Miana M, Jurado-López R et al. A role for soluble ST2 in vascular remodeling associated with obesity in rats. PLoS ONE 2013;8:e79176.
15. Rimar D, Rosner I, Nov Y et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis & Rheumatology 2014;66:726-30.
16. Tago K, Takahiro N, Hayakawa M et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 2001;285:1377-83.
17. Terras S, Opitz E, Moritz RKC, Hoxtermann S, Gambichler T, Kreuter A. Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis. Ann Rheum Dis 2012;72:144-5.
18. Manetti M, Guiducci S, Ceccarelli C et al. Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Ann Rheum Dis 2011;70:1876-8.
19. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;37:18-25.
20. Sulli A, Pizzorni C, Smith V, Zampogna G, Ravera F, Cutolo M. Timing of transition between capillaroscopic patterns in systemic sclerosis. Arthritis Rheum 2012;64:821-5.
21. Caramaschi P, Volpe A, Canestrini S et al. Correlation between homocysteine plasma levels and nailfold videocapillaroscopic patterns in systemic sclerosis. Clin Rheumatol 2007;26:902-7.
22. Herrick AL, Moore TL, Murray AK et al. Nail-fold capillary abnormalities are associated with anti-centromere antibody and severity of digital ischaemia. Rheumatology 2010;49:1776-82.
23. Rankin AL, Mumm JB, Murphy E et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 2010;184:1526-35.
24. Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clinic Rev Allerg Immunol 2011;40:78-83.
25. Moinzadeh P, Aberer E, Ahmadi-Simab K et al. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2015;74:730-7.
26. Mathes AL, Christmann RB, Stifano G et al. Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin. Ann Rheum Dis 2014;73:1864-72.
27. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
28. Pascual-Figal DA, Januzzi JL. The biology of ST2: the international ST2 consensus panel. The American Journal of Cardiology 2015;115:3B-7B.